Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q2 2021 Results - Earnings Call Transcript

Reported Net Product Sales of $24.8 Million

Assertio Reports Second Quarter 2021 Financial Results

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

LAKE FOREST, Ill., June 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”).   Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and this matter is now closed.

Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Investors need to pay close attention to for Assertio Holdings (ASRT) stock based on the movements in the options market lately.

Implied Volatility Surging for Assertio Holdings (ASRT) Stock Options

Assertio Holdings Inc (NASDAQ: ASRT) announced yesterday that it is implementing a one-to-four reverse split of its issued and outstanding common stock. These are the details.

Assertio Holdings (ASRT) Stock: 1-For-4 Reverse Split

LAKE FOREST, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has filed a Certificate of Amendment to its certificate of incorporation (the “Certificate of Amendment”) to implement a one-to-four reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on May 18, 2021, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on May 18, 2021.

Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split

- Adjournment Solely to Vote on the Reverse Split and Proportional Authorized Shares Reduction Proposal (Proposal 2) and Increase in Authorized Shares Proposal (Proposal 3)

Assertio Holdings, Inc. Announces Adjournment of Annual Meeting of Shareholders

Acasti Pharma

T2 Biosystems

Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Investors Need to Watch In 2021

The stock price of Assertio Holdings Inc (NASDAQ: ASRT) increased by over 30% pre-market. This is why it happened.

ASRT Stock: Over 30% Increase Pre-Market Explanation

Assertio Holdings' (ASRT) CEO Dan Peisert on Q1 2021 Results - Earnings Call Transcript

Reported Net Product Sales of $26.4 Million, Compared to Prior Year Pro-Forma Net Products Sales of $28.3 Million

Assertio Reports First Quarter 2021 Financial Results

Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, and Continuous Online Physician Care Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, and Continuous Online Physician Care

Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)

LAKE FOREST, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2021 financial results on Thursday, May 6, 2021, after the close of markets. Following the release of its financial results, Assertio's management will host a conference call beginning at 4:30 p.m. eastern time.

Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021

Assertio has endured a difficult few years that began with its $1.5bn purchase of opioid treatment Nucynta in 2015 under its former name DepoMed.

Assertio Holdings: Bankruptcy, Sale Or Success - How Management Can Rapidly Deliver Triple-Digit Upside

Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q4 2020 Results - Earnings Call Transcript

Full Year Net Product Sales of $93.5 Million; Full Year Pro-Forma Revenue of $119.2 Million in Line with Guidance

Assertio Reports Fourth Quarter and Full Year 2020 Financial Results

Assertio (ASRT) Reports Next Week: What to Expect

LAKE FOREST, Ill., March 01, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that Dan Peisert, President and Chief Executive Officer of Assertio, will present at and participate in investor meetings at the 33rd Annual Roth Conference, held virtually, on Monday, March 15, 2021.

Assertio Holdings, Inc. to Present at Virtual Roth Conference on Monday, March 15, 2021

LAKE FOREST, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the close of markets. Following the release of its financial results, Assertio's management will host a conference call beginning at 4:30 p.m. eastern time.

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results After the Close of Markets on Thursday, March 11, 2021

LAKE FOREST, Ill., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.98 per share for gross proceeds of approximately $34.3 million.

Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million

LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000 shares of its common stock at a price of $0.98 per share, which is a premium to market based on applicable Nasdaq “minimum price” rules.

Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering

LAKE FOREST, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.62 per share for gross proceeds of approximately $14.0 million.

Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $14 Million

Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase 22.6 million common shares at $0.62 per share in a registered direct offering, for gross proceeds of $14 million. The offer price represents a discount of 21% from the last close price of $0.78 on Thursday.

Assertio Seeks To Raise $14M Via Equity At 21% Discount From Thursday's Close

LAKE FOREST, Ill., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 22,600,000 shares of its common stock at a purchase price of $0.62 per share in a registered direct offering.

News for Assertio Therapeutics Inc Stock (ASRT)